Champions Oncolog (CSBR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 04/30
| 10-2024 | 07-2024 | 04-2024 | 01-2024 | 10-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,041 | 1,313 | -7,276 | -7,167 | -4,637 |
| Depreciation Amortization | 848 | 449 | 1,867 | 1,410 | 929 |
| Accounts receivable | -664 | 565 | -1,991 | -197 | 53 |
| Accounts payable and accrued liabilities | -947 | -565 | 465 | -578 | -800 |
| Other Working Capital | -3,431 | -1,927 | -3,823 | -596 | -971 |
| Other Operating Activity | 2,181 | 476 | 4,621 | 2,807 | 2,024 |
| Operating Cash Flow | $28 | $311 | $-6,137 | $-4,321 | $-3,402 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -94 | N/A | -836 | -839 | -747 |
| Investing Cash Flow | $-94 | $N/A | $-836 | $-839 | $-747 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -74 | -37 | -146 | -108 | -74 |
| Common Stock Issued | 276 | N/A | 253 | 252 | 252 |
| Common Stock Repurchased | N/A | N/A | -634 | -634 | -634 |
| Financing Cash Flow | $202 | $-37 | $-527 | $-490 | $-456 |
| Beginning Cash Position | 2,618 | 2,618 | 10,118 | 10,118 | 10,118 |
| End Cash Position | 2,754 | 2,892 | 2,618 | 4,468 | 5,513 |
| Net Cash Flow | $136 | $274 | $-7,500 | $-5,650 | $-4,605 |
| Free Cash Flow | |||||
| Operating Cash Flow | 28 | 311 | -6,137 | -4,321 | -3,402 |
| Capital Expenditure | -94 | N/A | -836 | -839 | -747 |
| Free Cash Flow | -66 | 311 | -6,973 | -5,160 | -4,149 |